Rockwell Medical Announces Final Patient Dosed in PRIME Clinical Study

Rockwell Medical Announces Final Patient Dosed in PRIME Clinical Study

[at noodls] – Results Expected in First Quarter 2013 WIXOM, MI — (Marketwire) — 01/07/13 — Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and … more

View todays social media effects on RMTI

View the latest stocks trending across Twitter. Click to view dashboard

See who Rockwell is hiring next, click here to view

Share this post